细胞因子佐剂研究进展

doi:10.16431/j.cnki.1671-7236.2017.01.042

摘要/Abstract

摘要：

佐剂可通过增强巨噬细胞活性促进机体T细胞或B细胞的反应，参与半抗原或抗原免疫应答。随着人们对疫苗免疫效果的研究，细胞因子作为新型分子佐剂能增强疫苗的特异性免疫反应而被广泛研究。细胞因子在调节先天免疫和适应性免疫中发挥着关键作用，能增强疫苗的特异性免疫反应。最近几年，白细胞介素、干扰素、粒细胞巨噬细胞集落刺激因子、肿瘤坏死因子、趋化因子的研究已取得了很大进展，现对细胞因子佐剂的应用进展进行阐述，以期为其在将来的应用中提供参考。

关键词: 细胞因子; 佐剂; 干扰素; 白细胞介素

Abstract:

As an adjuvant, cytokine plays a key role in regulating the innate and adaptive immunity and enhancing the vaccine specific immune responses. The researches on the interleukin, interferon, granulocyte macrophage colony stimulating factors, tumor necrosis factors, and chemotactic factor have made considerable progress. Now we reviewed the cytokine adjuvant application in order to provide reference for the future application.

Key words: cytokine; adjuvant; interferon; interleukin

中图分类号:

S852.4

李世芳, 刘泽众, 常惠芸. 细胞因子佐剂研究进展[J]. 《中国畜牧兽医》, 2017, 44(1): 296-301.

LI Shi-fang, LIU Ze-zhong, CHANG Hui-yun. Research Progress on Cytokine Adjuvants[J]. , 2017, 44(1): 296-301.

参考文献

[1] 郑世军.动物分子免疫[M].北京:中国农业出版社,2015.
[2] Villarreal D O, Siefert R J, Weiner D B. Alarmin IL-33 elicits potent TB-specific cell-mediated responses[J]. Human Vaccines & Immunotherapeutics,2015, 11(8):1954-1960.
[3] Hu X, Cao Y, Meng Y, et al. A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2)[J]. Human Vaccines & Immunotherapeutics, 2015, 11(2):516-521.
[4] Kim N, Jeon Y W, Nam Y S, et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells[J]. Cytokine, 2016, 78:22-26.
[5] Zhang C, Wang B, Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot- and-mouth disease[J]. Virology Journal, 2011, 8:7.
[6] Parhar R S, Zou M, Al-Mohanna F A, et al. IL-12 immunotherapy of Braf (V600E)-induced papillary thyroid cancer in a mouse model[J]. Laboratory Investigation, 2016, 96(1):89-97.
[7] Jalah R, Patel V, Kulkarni V, et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques[J]. Human Vaccines & Immunotherapeutics, 2012, 8(11):1620-1629.
[8] Naderi M, Saeedi A, Moradi A, et al. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity[J]. Virologica Sinica, 2013, 28(3):167-173.
[9] Croci S, Nanni P, Palladini A, et al. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis[J]. Breast Cancer Research, 2015, 17:70.
[10] Cha E, Graham L, Manjili M H, et al. IL-7+IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo[J]. Breast Cancer Research and Treatment, 2010, 122(2):359-369.
[11] Huang P L, Hou M S, Wang S W, et al. Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis[J]. Skeletal Muscle, 2015, 5:33.
[12] Dai S, Zhou X, Wang B, et al. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(⁺) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells[J]. J Mol Med (Berl), 2006, 84(12):1067-1076.
[13] Lim K L, Jazayeri S D, Yeap S K, et al. Co-administration of avian influenza virus H5 plasmid DNA with chicken IL-15 and IL-18 enhanced chickens immune responses[J].Bmc Veterinary Research, 2012, 8:132.
[14] Lian H, Jin N, Li X, et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin[J]. Cancer Immunology Immunotherapy, 2007, 56(2):181-192.
[15] Hu K, He X, Yu F, et al. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis[J]. Immunological Investigations, 2011, 40(3):265-278.
[16] He X, Wang J, Zhao F, et al. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatousmouse[J]. Immunologic Research, 2012, 52(3):240-249.
[17] Wu B, Zou Q, Hu Y, et al. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8(+) T cell responses against a HBV DNA vaccine in mice[J]. Human Vaccines & Immunotherapeutics, 2013, 9(10):2133-2141.
[18] Hong S, Qian J, Li H, et al. CpG or IFN-alpha are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma[J]. Cancer Immunology Immunotherapy, 2012, 61(4):561-571.
[19] Cheng Z P, Cheng A C, Wang M S, et al. Effect of cell mediated immunity regulation of duck enhanced by duck IFN-γ eukaryon expression plasmid and inoculated with DPV attenuated vaccine by gene-gun[J]. Frontiers of Agriculture in China, 2008, 2(3):343-347.
[20] Davies G, Vaccine Adjuvants:Methods and Protocols[M].New York:Humana Press, 2010.
[21] Bandera A, Trabattoni D, Ferrario G, et al. Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis[J]. Infection, 2008, 36(4):368-373.
[22] Milanés-Virelles M T, García-García I, Santos-Herrera Y, et al. Adjuvant interferon gamma in patients with pulmonary atypical mycobacteriosis:A randomized, double-blind, placebo-controlled study[J]. Bmc Infectious Diseases, 2008, 8:17.
[23] Morrow M P, Yan J, Pankhong P, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques[J]. Molecular Therapy, 2010, 18(9):1714-1723.
[24] Wen Q, Xiong W, He J, et al. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions[J]. Journal of Translational Medicine, 2016, 14:41.
[25] Noh K H, Park Y M, Kim H S, et al. GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity[J]. Bmc Immunology, 2014, 15:48.
[26] Zhang H, Qian P, Peng B, et al. A novel subunit vaccine co-expressing GM-CSF and PCV2b Cap protein enhances protective immunity against porcine circovirus type 2 in piglets[J]. Vaccine, 2015, 33(21):2449-2456.
[27] Seo S H, Han H D, Noh K H, et al. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8(⁺) T cell-mediated anti-tumor immunity[J]. Clinical & Experimental Metastasis, 2009, 26(3):179-187.
[28] Mittendorf E A, Holmes J P, Ponniah S, et al. The E75 HER2/neu peptide vaccine[J]. Cancer Immunology Immunotherapy, 2008, 57(10):1511-1521.
[29] Wen J, Hao W, Fan Y, et al. Co-delivery of LIGHT expression plasmid enhances humoral and cellular immune responses to HIV-1 Nef in mice[J]. Archives of Virology, 2014, 159(7):1663-1669.
[30] Liu H Z, Song R, Zhang J X,et al. Molecular cloning, recombinant expression, and funtional characterization of APRIL (TNFSF13) in cat (Felis catus)[J]. Anmial Biotechnology, 2016, 27(1):1-8.
[31] Kathuria N, Kraynyak K A, Carnathan D, et al. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant[J]. Human Vaccines & Immunotherapeutics, 2012, 8(11):1607-1619.
[32] Liu Z Q, Ravindranathan R, Li J, et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy[J]. Onco Immunology, 2015, 5(3):e1091554.
[33] Hartoonian C, Sepehrizadeh Z, Mahdavi M, et al. Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20(CCL20) gene as immunoadjuvant[J]. Molecular Biology Reports, 2014, 41(9):5943-5952.
[34] Kutzler M A, Kraynyak K A, Nagle S J, et al. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo[J]. Gene Therapy, 2010, 17(1):72-82.